Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Approves Entyvio’s Crohn’s Disease Indication and More
May 23, 2019
- JPMA Prods Revamp of PMP, Launch Premiums, Comparator Selection Criteria towards 2020 Reform
May 22, 2019
- Minister Says Kymriah Pricing Appropriate Even with Low Cost Disclosure Ratio
May 22, 2019
- MHLW Planning to Launch Report System on Inappropriate Detailing Activity as Early as Summer
May 21, 2019
- Govt, Industry Share Views on Challenges in Data Use, Drug Pricing
May 21, 2019
- 74 Suspected Violations Found in Sales Reps’ Advertising Activities: MHLW
May 21, 2019
- Eli Lilly Ordered to Issue Blue Letter on Verzenio
May 20, 2019
- Kymriah’s Impact on Health Insurance Finances Limited for Now: Health Minister
May 20, 2019
- LDP Lawmaker Group Discusses Measures for APIs to Ensure Stable Generic Drug Supplies
May 17, 2019
- Chugai’s Entrectinib Up for Review for NTRK Tumors on May 30; Label Expansions for Lynparza, Cyramza Also on Agenda
May 17, 2019
- MHLW Compiles Optimal Promotion Guidelines for Kymriah
May 16, 2019
- Coefficients for Cost-Based Pricing Formula Updated: Chuikyo
May 16, 2019
- As Kymriah Fetches Highest List Price, Policymakers Talk over Difficulty in Cell Therapy Pricing
May 16, 2019
- Alnylam’s siRNA Drug Patisiran Up for MHLW Panel Review on May 28
May 16, 2019
- Japan OKs Listing of Trelegy, Erleada, and More; GSK’s COPD Hopeful to Face Cost-Effectiveness Analysis
May 15, 2019
- Opdivo to Face CEA-Based Price Tweaks on Aug. 1
May 15, 2019
- Kymriah Gets 33.5 Million Yen Price Tag, Peak Sales Put at 7.2 Billion Yen
May 15, 2019
- 87% of Drug Makers Say 2018 Pricing Reform Hit Their R&D, Businesses: MHLW Survey
May 15, 2019
- Newly Sworn In Chief Gives “4 First” Pep Talk to PMDA Staffers
May 14, 2019
- Kymriah Likely to Fetch 33 Million Yen Price Tag, Collategene to Skip Listing
May 14, 2019
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…